Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115095
Chunk: 278

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 278
---
nur Acquisition Agreement (including the amendment thereto) in the forms filed as exhibits to the registration statement of which this prospectus is a part. You should read the Semnur Acquisition Agreement (including the amendment thereto) for a complete understanding of all of their respective terms.**

<div align='center'>177</div>

**Semnur-Denali Business Combination

On August 30, 2024, Semnur entered into the Semnur Business Combination Agreement with Denali and Denali Merger Sub.

The Semnur Business Combination Agreement provides that, among other things, (i) on the terms and subject to the conditions set forth therein, Denali Merger Sub will merge with and into Semnur, with Semnur surviving as a wholly owned subsidiary of Denali (the “Semnur Business Combination”), and (ii) prior to the closing of the Semnur Business Combination, Denali will migrate to and domesticate as a Delaware corporation in accordance with Section 388 of the DGCL, and de-register in the Cayman Islands in accordance with Section 206 of the Cayman Companies Act (the “Semnur Domestication”). Upon the closing of the Semnur Business Combination, it is anticipated that Denali will change its name to “Semnur Pharmaceuticals, Inc.” (“New Semnur”). Shares of Denali common stock following the Semnur Domestication are hereinafter referred to as “New Semnur Common Shares”. Shares of Denali Series A preferred stock following the Semnur Domestication are hereinafter referred to as “New Semnur Preferred Shares”. Warrants to purchase New Semnur Common Shares following the Semnur Domestication are hereinafter referred to as “New Semnur Warrants”.

In connection with the execution and delivery of the Semnur Business Combination Agreement, Denali Capital Global Investments LLC, a Cayman Islands limited liability company (the “Denali Sponsor”), and the Company entered into a Sponsor Interest Purchase Agreement (the “SIPA”) dated August 30, 2024 (the “Signing Date”). Pursuant to the SIPA, the Company agreed to purchase 500,000 Class B ordinary shares, par value $0.0001 per share (the “Purchased Interests”), of Denali that are currently held by the Denali Sponsor. The aggregate consideration for the purchase and sale of the Purchased Interests is as follows: (i) $2,000,000